Int. Journal of Clinical Pharmacology and Therapeutics, Volume 61 (2023) - April (181 - 188)

Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients

Qi Shen1, Tiantao Gao1, Jin Xiang1, Ping Feng1, Xinghong Liu2, Li Zheng1
1 Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, and 2 West China School of Pharmacy, Sichuan University, Chendu, China

Add to Cart  

 

DOI 10.5414/CP204224

Abstract

Purposes: The physiological and pathological conditions of individuals could influence the absorption and metabolism of drugs in vivo, so this study assessed the bioequivalence and pharmacokinetics of lenalidomide 25 mg capsules (test formulation) and Revlimid 25 mg capsules (reference formulation) in Chinese patients with multiple myeloma (MM).
Materials and methods: A multicenter, open-label, randomized, two-period, crossover trial was established to evaluate a single capsule of test and reference formulations under fasting conditions. Pharmacokinetic parameters were assessed, and adverse events (AEs) were monitored throughout.
Results: Overall, 40 patients with MM completed the study. 17 AEs were reported, among which there was 1 serious event during the study. Geometric ratios for the maximum plasma concentration (Cmax) (98.50%; 90% confidence interval (CI), 91.89 – 105.60%), area under the plasma concentration-time curve (AUC) from time 0 to the last measurable concentration (AUC) (94.74%; CI, 92.07 – 97.50%), and AUC from time 0 to infinity (AUC(0–∞)) (95.55%; CI, 93.07 – 98.09%) all met bioequivalence criteria. Statistics of the data of 39 patients after oral administration of lenalidomide (both test and reference formulation) demonstrated that plasma exposure tends to increase with age.
Conclusion: The two formulations of lenalidomide 25 mg displayed similar pharmacokinetic profiles and were bioequivalent. Age was verified to change the pharmacokinetics of lenalidomide, as increasing age was correlated with higher total exposure.

Author Details

Authors

Departments

  • 1 Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, and
  • 2 West China School of Pharmacy, Sichuan University, Chendu, China

Address

Li Zheng, Medical PhD, Chief Physician
Clinical Trial Center
National Medical Products Administration
Key Laboratory for Clinical Research and
Evaluation of Innovative Drugs
West China Hospital, Sichuan University
Chengdu 610041, China
Email: [email protected]

Log in for Subscribers

Citation

Qi Shen, Tiantao Gao, Jin Xiang, Ping Feng, Xinghong Liu, Li Zheng. Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients
. Int J Clin Pharmacol Ther. 2023; 61: 181-188. doi: 10.5414/CP204224. Pubmed: https://pubmed.ncbi.nlm.nih.gov/36683548/; PMID: 36683548.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart